AstraZeneca PLC(AZN)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
AZN | 246.25 B | 23.77x | 6.40% | 17.02% | $6.68 | 21.97% | 0.64x | 2.05% | $212.71 | $153.41 |
AZN.L | 18.70 T | 2387.33x | 6.40% | 17.02% | $5.05 | 21.97% | 0.64x | 0.03% | $15729.35 | $9891.35 |
HLN.L | 3.08 T | 1943.89x | 2.20% | 14.55% | $0.18 | 10.09% | 0.50x | 0.02% | $416.02 | $317.78 |
HIK.L | 332.47 B | 1207.52x | 4.20% | 11.32% | $1.33 | 15.41% | 0.77x | 0.05% | $1864.16 | $1186.46 |
Peer Valuation & Performance Analysis
Peer group analysis for AstraZeneca PLC (AZN) compared to its primary competitors (including AZN.L, HLN.L, HIK.L) reveals distinct metrics. AZN trades at a valuation discount relative to its competitors, with a P/E ratio of 23.8x versus the peer average of 1846.2x (representing a 99% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, AZN's revenue growth of 6.4% exceeds the peer average of 4.3%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 17.0% compared to the peer average of 14.3%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• AZN ranks #1 in P/E ratio, #1 in revenue growth, and #1 in profit margins
• Average ranking: #1 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-08 | $159.80 | $160.05 | $156.72 | $158.78 | 3,488,700 | -0.84% |
| 2026-10-07 | $159.12 | $161.29 | $158.53 | $160.12 | 2,458,400 | +0.95% |
| 2026-10-06 | $159.80 | $159.96 | $156.26 | $158.61 | 2,050,200 | +1.33% |
| 2026-10-05 | $156.76 | $157.20 | $154.81 | $156.53 | 2,256,000 | -0.24% |
| 2026-10-02 | $158.46 | $158.80 | $156.41 | $156.90 | 3,035,400 | -0.51% |
| 2026-10-01 | $160.77 | $161.33 | $157.54 | $157.70 | 3,377,400 | -2.33% |
| 2026-09-30 | $164.47 | $164.48 | $161.46 | $161.47 | 2,225,200 | -1.67% |
| 2026-09-29 | $165.09 | $166.47 | $163.24 | $164.21 | 3,372,100 | -1.17% |
| 2026-09-28 | $165.69 | $167.52 | $165.39 | $166.15 | 1,726,600 | -0.26% |
| 2026-09-25 | $166.16 | $166.81 | $164.60 | $166.58 | 2,067,900 | +1.23% |
| 2026-09-24 | $162.91 | $166.25 | $162.91 | $164.56 | 3,188,400 | +0.75% |
| 2026-09-23 | $166.58 | $167.59 | $163.33 | $163.33 | 2,361,200 | -2.99% |
| 2026-09-22 | $167.84 | $169.35 | $166.74 | $168.37 | 2,306,200 | +0.16% |
| 2026-09-21 | $168.45 | $169.00 | $167.11 | $168.10 | 2,937,800 | +1.22% |
| 2026-09-18 | $167.15 | $167.83 | $165.54 | $166.08 | 3,060,300 | -0.04% |
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.